21CFR
粤妆评合规
2026-07-27
21 CFR Part 333 Subpart B - First Aid Antibiotic Drug ProductsSubpart B—First Aid Antibiotic Drug Products§ 333.101 Scope.(a) An over-the-counter first aid antibiotic drug product in a form suitable for topical administration is generally recognized
21CFR
粤妆评合规
2026-07-27
21 CFR Part 347 - Skin Protectant Drug Products for Over-the-Counter Human UsePART 347—SKIN PROTECTANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:58 FR 54462, Oct. 21, 1993, unless otherwi
21CFR
粤妆评合规
2026-07-27
21 CFR Part 350 - Antiperspirant Drug Products for Over-the-Counter Human UsePART 350—ANTIPERSPIRANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:68 FR 34291, June 9, 2003, unless otherwise
21CFR
粤妆评合规
2026-07-27
21 CFR Part 352 - Sunscreen Drug Products for Over-the-Counter Human Use [Stayed Indefinitely]PART 352—SUNSCREEN DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE [STAYED INDEFINITELY]Authority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:64 FR 2768
21CFR
粤妆评合规
2026-07-27
21 CFR Part 355 - Anticaries Drug Products for Over-the-Counter Human UsePART 355—ANTICARIES DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:60 FR 52507, Oct. 6, 1995, unless otherwise noted.Ed
21CFR
粤妆评合规
2026-07-27
21 CFR Part 358 - Miscellaneous External Drug Products for Over-the-Counter Human UsePART 358—MISCELLANEOUS EXTERNAL DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USEAuthority:21 U.S.C. 321, 351, 352, 353, 355, 360, 371.Source:55 FR 33255, Aug. 14, 1990,
21CFR
粤妆评合规
2026-07-27
21 CFR Part 358 Subpart D—Ingrown Toenail Relief Drug ProductsSubpart D—Ingrown Toenail Relief Drug ProductsSource:68 FR 24348, May 7, 2003, unless otherwise noted.§ 358.301 Scope.(a) An over-the-counter ingrown toenail relief drug product in a form
OTC申报
粤妆评合规
2026-07-18
2026年FDA OTC专论M003明确急救消毒产品仅限小割伤、擦伤和轻微烧伤用途,非豁免产品须在32°C、10%血清条件下完成3-log杀菌效力测试。中国出口企业需完成FDA注册、NDC列名、cGMP合规及Drug Facts标签,不得扩展至手消毒或医疗用途宣称。
OTC申报
粤妆评合规
2026-07-14
2026年多家中国企业指甲真菌液产品通过FDA NDC注册进入美国市场。OTC专论M005允许7类活性成分用于抗真菌OTC药品,但适应症仅限足癣、股癣和体癣,未明确收录甲癣。企业须精准设计标签宣称,区分抑制真菌生长与治疗甲癣的合规边界,并完成FDA企业注册与NDC产品列名。
OTC申报
粤妆评合规
2026-07-14
2026年多款去疣剂产品通过FDA的NDC注册成功进入美国市场,OTC专论M028是去疣剂合规的核心依据。去疣剂唯一允许的活性成分为水杨酸,浓度因剂型不同分为5%至40%三档。出口企业须完成FDA企业注册、NDC产品列名、Drug Facts标签合规及cGMP验证,方可合法销售。本文详解全流程实操要点。